Cargando…
Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
Autores principales: | Hottinger, Andreas F., de Micheli, Rita, Guido, Vanessa, Karampera, Alexandra, Hagmann, Patric, Du Pasquier, Renaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225924/ https://www.ncbi.nlm.nih.gov/pubmed/30465016 http://dx.doi.org/10.1212/NXI.0000000000000439 |
Ejemplares similares
-
Anti-Hu limbic encephalitis preceding the appearance of mediastinal germinoma by 9 years
por: Silsby, Matthew, et al.
Publicado: (2020) -
Anti-Adenylate Kinase 5 Encephalitis With Histologic Evidence of CNS Vasculitis
por: Vicino, Alex, et al.
Publicado: (2021) -
Faciobrachio-crural dystonic seizures in LGI1 limbic encephalitis: A treatable cause of falls
por: Ismail, Fatme Seval, et al.
Publicado: (2015) -
Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015) -
Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)